The aforementioned phrase refers to a series of directives issued by the previous presidential administration in the United States concerning the cost and availability of pharmaceutical medications. These directives aimed to lower drug prices for American consumers and reform aspects of the pharmaceutical market. For instance, one proposal involved allowing the importation of certain prescription drugs from Canada, while another focused on rebates negotiated by pharmacy benefit managers (PBMs).
The potential impacts of these executive actions were significant, touching upon issues of healthcare access, affordability, and the pharmaceutical industry’s business practices. Historically, prescription drug prices in the U.S. have been considerably higher than in many other developed nations. Therefore, attempts to control these costs often generated considerable debate among policymakers, pharmaceutical companies, patient advocacy groups, and the public.
